• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

初诊时血小板计数高是原发性血小板增多症患者血栓形成的保护因素。

High platelet count at diagnosis is a protective factor for thrombosis in patients with essential thrombocythemia.

机构信息

Department of Cellular Biotechnologies and Hematology, University "Sapienza", Rome, Italy.

Department of Cellular Biotechnologies and Hematology, University "Sapienza", Rome, Italy.

出版信息

Thromb Res. 2017 Aug;156:168-171. doi: 10.1016/j.thromres.2017.06.023. Epub 2017 Jun 21.

DOI:10.1016/j.thromres.2017.06.023
PMID:28662484
Abstract

To assess the role of platelet (PLT) count for thrombotic complications in Essential Thrombocythemia (ET), 1201 patients followed in 11 Hematological centers in the Latium region were retrospectively evaluated. At multivariate analysis, the following factors at diagnosis were predictive for a worse Thrombosis-free Survival (TFS): the occurrence of previous thrombotic events (p=0.0004), age>60years (p=0.0044), spleen enlargement (p=0.042) and a lower PLT count (p=0.03). Receiver Operating Characteristic (ROC) analyses based on thrombotic events during follow-up identified a baseline platelet count of 944×10/l as the best predictive threshold: thrombotic events were 40/384 (10.4%) in patients with PLT count >944×10/l and 109/817 (13.3%) in patients with PLT count <944×10/l, respectively (p=0.04). Patients with PLT count <944×10/l were older (median age 60.4years. vs 57.1years., p=0.016), had a lower median WBC count (8.8×10/l vs 10.6×10/l, p<0.0001), a higher median Hb level (14.1g/dl vs 13.6g/dl, p<0.0001) and a higher rate of JAK-2-V617F positivity (67.2% vs 41.6%, p<0.0001); no difference was observed as to thrombotic events before diagnosis, spleen enlargement and concomitant Cardiovascular Risk Factors. In conclusion, our results confirm the protective role for thrombosis of an high PLT count at diagnosis. The older age and the higher rate of JAK-2 V617F positivity in the group of patients with a baseline lower PLT count could in part be responsible of this counterintuitive finding.

摘要

为了评估血小板(PLT)计数在原发性血小板增多症(ET)中的血栓并发症中的作用,对 11 个拉齐奥地区血液中心随访的 1201 例患者进行了回顾性评估。多变量分析显示,以下诊断时的因素预测血栓无复发生存率(TFS)较差:既往血栓事件(p=0.0004)、年龄>60 岁(p=0.0044)、脾脏肿大(p=0.042)和较低的 PLT 计数(p=0.03)。基于随访期间血栓事件的受试者工作特征(ROC)分析,确定基线血小板计数 944×10/L 为最佳预测阈值:血小板计数>944×10/L 的患者中发生血栓事件的有 40/384(10.4%),血小板计数<944×10/L 的患者中发生血栓事件的有 109/817(13.3%)(p=0.04)。血小板计数<944×10/L 的患者年龄更大(中位数年龄 60.4 岁,vs. 57.1 岁,p=0.016),白细胞计数中位数更低(8.8×10/L,vs. 10.6×10/L,p<0.0001),血红蛋白水平中位数更高(14.1g/dl,vs. 13.6g/dl,p<0.0001),JAK-2-V617F 阳性率更高(67.2%,vs. 41.6%,p<0.0001);诊断前的血栓事件、脾脏肿大和并存心血管危险因素方面无差异。总之,我们的结果证实了高血小板计数在诊断时对血栓形成的保护作用。在基线血小板计数较低的患者组中,年龄较大和 JAK-2 V617F 阳性率较高可能部分解释了这一矛盾的发现。

相似文献

1
High platelet count at diagnosis is a protective factor for thrombosis in patients with essential thrombocythemia.初诊时血小板计数高是原发性血小板增多症患者血栓形成的保护因素。
Thromb Res. 2017 Aug;156:168-171. doi: 10.1016/j.thromres.2017.06.023. Epub 2017 Jun 21.
2
Role of blood cells dynamism on hemostatic complications in low-risk patients with essential thrombocythemia.血细胞动态变化在原发性血小板增多症低风险患者止血并发症中的作用。
Intern Emerg Med. 2015 Jun;10(4):451-60. doi: 10.1007/s11739-015-1186-8. Epub 2015 Jan 14.
3
Clinico-hematological profile and thrombotic/hemorrhagic events in 150 chinese patients with essential thrombocythemia.150例中国原发性血小板增多症患者的临床血液学特征及血栓形成/出血事件
Leuk Res. 2018 Jun;69:1-6. doi: 10.1016/j.leukres.2018.03.013. Epub 2018 Mar 27.
4
Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of 2001 WHO Versus 2008/2016 WHO Criteria in a Large Single-center Cohort.原发性血小板增多症的临床和预后特征:2001 年 WHO 标准与 2008/2016 年 WHO 标准在一个大型单中心队列中的比较。
Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):e328-e333. doi: 10.1016/j.clml.2020.11.003. Epub 2020 Nov 6.
5
Influence of platelet and white blood cell counts on major thrombosis - analysis from a patient registry in essential thrombocythemia.血小板和白细胞计数对主要血栓形成的影响——来自原发性血小板增多症患者登记处的分析
Eur J Haematol. 2016 Dec;97(6):511-516. doi: 10.1111/ejh.12759. Epub 2016 May 23.
6
Thrombotic complications in essential thrombocythemia (ET): clinical facts and biochemical riddles.原发性血小板增多症(ET)中的血栓形成并发症:临床事实与生化谜团
Blood Cells Mol Dis. 2006 May-Jun;36(3):379-84. doi: 10.1016/j.bcmd.2005.12.031. Epub 2006 Mar 24.
7
[Correlation of thrombosis with increased platelet turnover in essential thrombocythemia].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006 Feb;14(1):165-7.
8
Altered plasma fibrin clot properties in essential thrombocythemia.原发性血小板增多症患者的血浆纤维蛋白凝块特性改变。
Platelets. 2016;27(2):110-6. doi: 10.3109/09537104.2015.1042967. Epub 2015 May 19.
9
Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients.脾脏肿大是原发性血小板增多症血栓形成的一个危险因素:对 1297 例患者的评估。
Am J Hematol. 2016 Mar;91(3):318-21. doi: 10.1002/ajh.24269.
10
The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.血小板活化与功能受损的悖论:血小板与血管性血友病因子的相互作用,以及原发性血小板增多症和真性红细胞增多症中血栓形成和出血表现的病因。
Semin Thromb Hemost. 2006 Sep;32(6):589-604. doi: 10.1055/s-2006-949664.

引用本文的文献

1
A Review About the Assessment of the Bleeding and Thrombosis Risk for Patients With Myeloproliferative Neoplasms Scheduled for Surgery.关于计划接受手术的骨髓增殖性肿瘤患者出血和血栓形成风险评估的综述
Cureus. 2024 Mar 12;16(3):e56008. doi: 10.7759/cureus.56008. eCollection 2024 Mar.
2
Clinical Characteristics and Management of Cerebral Venous Sinus Thrombosis in Patients with Essential Thrombocythemia.原发性血小板增多症患者脑静脉窦血栓形成的临床特征与管理
Neuropsychiatr Dis Treat. 2021 Apr 22;17:1195-1206. doi: 10.2147/NDT.S294712. eCollection 2021.
3
Antithrombotic Management in Ischemic Stroke with Essential Thrombocythemia: Current Evidence and Dilemmas.
原发性血小板增多症所致缺血性脑卒中的抗栓治疗:当前的证据与困境
Med Princ Pract. 2021;30(5):412-421. doi: 10.1159/000516471. Epub 2021 Apr 13.
4
Clinical insights into the origins of thrombosis in myeloproliferative neoplasms.临床视角下骨髓增殖性肿瘤中血栓形成的起源。
Blood. 2021 Mar 4;137(9):1145-1153. doi: 10.1182/blood.2020008043.
5
Essential thrombocythemia treatment algorithm 2018.2018 年原发性血小板增多症治疗算法
Blood Cancer J. 2018 Jan 10;8(1):2. doi: 10.1038/s41408-017-0041-8.